Orion (ORNBV.HE)

Executive Summary

Orion is a Finnish pharmaceutical company with a century-long history, focusing on human and veterinary pharmaceuticals, active pharmaceutical ingredients, and diagnostics. The company operates globally and is publicly traded (ORNBV.HE). With a Phase 2 stage pipeline, Orion is advancing several innovative therapies in oncology, neurology, and respiratory areas. Key pipeline assets include ODM-208 (CYP11A1 inhibitor for metastatic castration-resistant prostate cancer) in Phase 2, and ODM-203 (FGFR/VEGFR inhibitor) in Phase 2. Orion’s commercial portfolio generates stable revenue, supporting R&D. The company benefits from a strong balance sheet and strategic partnerships (e.g., Bayer for darolutamide). However, pipeline diversification and late-stage data readouts remain critical for future growth. Near-term catalysts include data from ongoing Phase 2 trials and potential regulatory filings for ODM-208.

Upcoming Catalysts (preview)

• Q4 2025ODM-208 Phase 2 data update in mCRPC60% success
• H1 2026ODM-203 Phase 2 interim results in solid tumors50% success
• 2026Potential partnership or licensing deal for pipeline assets40% success